The announcement of a securities fraud class action lawsuit against Novo Nordisk A/S is likely to negatively impact its stock price in the short term due to potential legal liabilities and investor concerns. The high relevance and importance are due to the direct mention of the lawsuit and its potential financial implications for the company.